{
    "medicine_id": "fc374c33ff366884c45fbbe1956274bd68d55b97",
    "platform_id": "DB05718",
    "metadata": {
        "name": "Stelara 5 mg Solution",
        "composition": "5 mg Maxy G34",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in adverse effects chemotherapy and neutropenics",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Maxy G34 is a PEGylated proprietary G CSF variant designed to be administered as a single subcutaneous injection once per chemotherapy cycle Maxygen has made changes in the G CSF gene sequence that code for novel PEGylation sites in the resulting protein In contrast to the currently marketed PEGylated G CSF Maxy G34 has multiple PEG groups attached at specifically selected sites on the molecule In several in vivo models Maxy G34 has demonstratedimproved pharmacokinetics and pharmacodynamics compared to the currently marketed PEGylated G CSF",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00531",
                        "description": "The risk or severity of pulmonary toxicity can be increased when Maxy G34 is combined with Cyclophosphamide"
                    },
                    {
                        "drugbank-id": "DB00309",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Maxy G34 is combined with Vindesine"
                    },
                    {
                        "drugbank-id": "DB00361",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Maxy G34 is combined with Vinorelbine"
                    },
                    {
                        "drugbank-id": "DB00541",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Maxy G34 is combined with Vincristine"
                    },
                    {
                        "drugbank-id": "DB00570",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Maxy G34 is combined with Vinblastine"
                    },
                    {
                        "drugbank-id": "DB05168",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Maxy G34 is combined with Vintafolide"
                    },
                    {
                        "drugbank-id": "DB11641",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Maxy G34 is combined with Vinflunine"
                    },
                    {
                        "drugbank-id": "DB13374",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Maxy G34 is combined with Vincamine"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}